Julio Sandoval Zarate1, Carlos Jerjes-Sanchez2, Alicia Ramirez-Rivera3, Tomas Pulido Zamudio4, Pedro Gutierrez-Fajardo5, Jose Elizalde Gonzalez6, Mario Seoane Garcia De Leon7, Miguel Beltran Gamez8, Francisco Moreno Hoyos Abril9, Rodolfo Parra Michel10, Humberto Garcia Aguilar11. 1. Executive Committee, Mexico; National Coordinator, Mexico; Instituto Nacional de Cardiologia "Ignacio Chavez", Mexico. 2. Executive Committee, Mexico; Instituto de Cardiologia y Medicina Vascular, TEC Salud, San Pedro Garza García, Mexico; Centro de Investigación Biomédica del Hospital Zambrano Hellion, Escuela de Medicina, Tecnologico de Monterrey, Mexico. Electronic address: jerjes@prodigy.net.mx. 3. Executive Committee, Mexico; Hospital de Cardiología No 34, IMSS, Monterrey, Mexico. 4. Executive Committee, Mexico; Instituto Nacional de Cardiologia "Ignacio Chavez", Mexico. 5. Executive Committee, Mexico; Hospital Mac Bernardette, Guadalajara, Mexico. 6. Executive Committee, Mexico; Instituto Nacional de la Nutrición "Salvador Zubiran", Mexico. 7. Executive Committee, Mexico; Centro Medico ABC, Mexico. 8. Executive Committee, Mexico; Instituto de Seguridad y Servicios Sociales del Estado de Baja California, Mexico. 9. Executive Committee, Mexico; Hospital Universitario "Dr. José E. González", Monterrey, Mexico. 10. Executive Committee, Mexico; Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Mexico. 11. Executive Committee, Mexico; Centro Medico Nacional "20 de Noviembre" ISSSTE, Mexico.
Abstract
OBJECTIVE: REMEHIP is a prospective, multicentre registry on pulmonary hypertension. The main objective will be to identify the clinical profile, medical care, therapeutic trends and outcomes in adult and pediatric Mexican patients with well-characterized pulmonary hypertension. METHODS: REMEHIP a multicenter registry began in 2015 with a planned recruitment time of 12 months and a 4-year follow-up. The study population will comprise a longitudinal cohort study, collecting data on patients with prevalent and incident pulmonary hypertension. Will be included patients of age >2 years and diagnosis of pulmonary hypertension by right heart catheterization within Group 1 and Group 4 of the World Health Organization classification. The structure, data collection and data analysis will be based on quality current recommendations for registries. The protocol has been approved by institutional ethics committees in all participant centers. All patients will sign an informed consent form. Currently in Mexico, there is a need of observational registries that include patients with treatment in the everyday clinical practice so the data could be validated and additional information could be obtained versus the one from the clinical trials. In this way, REMEHIP emerges as a link among randomized clinical trials developed by experts and previous Mexican experience.
OBJECTIVE: REMEHIP is a prospective, multicentre registry on pulmonary hypertension. The main objective will be to identify the clinical profile, medical care, therapeutic trends and outcomes in adult and pediatric Mexican patients with well-characterized pulmonary hypertension. METHODS: REMEHIP a multicenter registry began in 2015 with a planned recruitment time of 12 months and a 4-year follow-up. The study population will comprise a longitudinal cohort study, collecting data on patients with prevalent and incident pulmonary hypertension. Will be included patients of age >2 years and diagnosis of pulmonary hypertension by right heart catheterization within Group 1 and Group 4 of the World Health Organization classification. The structure, data collection and data analysis will be based on quality current recommendations for registries. The protocol has been approved by institutional ethics committees in all participant centers. All patients will sign an informed consent form. Currently in Mexico, there is a need of observational registries that include patients with treatment in the everyday clinical practice so the data could be validated and additional information could be obtained versus the one from the clinical trials. In this way, REMEHIP emerges as a link among randomized clinical trials developed by experts and previous Mexican experience.